s covalent drugs have unique therapeutic benefits because they are highly targeted, are effective against mutations and have long duration of action
. Avila is developing a pipeline of
novel, protein silencing drugs with a current focus on viral infection, cancer, and autoimmune diseases. Avila was founded in 2007 and is based in Waltham, Massachusetts. For additional information, please visit http://www.avilatx.com.